How do I select the initial two‑drug antihypertensive combination and a third‑line agent based on a patient’s age, ethnicity, and comorbidities?

Selecting Combination Antihypertensive Therapy and Third-Line Agents

Initial Two-Drug Combination Strategy

For patients under 55 years (non-Black): Start with an ACE inhibitor or ARB combined with a calcium-channel blocker (CCB). 1

For patients over 55 years or Black patients of any age: Start with a CCB combined with a thiazide-like diuretic. 1

Age-Based Selection

• Adults <55 years (non-Black): The preferred initial combination is an ACE inhibitor (e.g., lisinopril 10–20 mg) or ARB (e.g., losartan 50–100 mg) plus a CCB (e.g., amlodipine 5–10 mg). 1
• Adults ≥55 years: Begin with a CCB (amlodipine 5–10 mg) plus a thiazide-like diuretic (chlorthalidone 12.5–25 mg preferred over hydrochlorothiazide). 1
• Elderly ≥80 years: Treat only if stage 2 hypertension (≥160/100 mmHg), using standing BP measurements and accounting for frailty. 1

Ethnicity-Based Selection

• Black patients (any age): Initial therapy should be a CCB combined with either a thiazide-like diuretic or an ARB (ARB preferred over ACE inhibitor if combining with CCB). 1
• Black patients from Sub-Saharan Africa: Specifically consider CCB + thiazide diuretic or CCB + RAS blocker. 1
• Hispanic patients: CCB-based regimens are more effective due to lower renin activity; CCB + thiazide diuretic or CCB + ACE inhibitor/ARB are appropriate. 2

Comorbidity-Driven Selection

Heart Failure with Reduced Ejection Fraction (HFrEF):

• Use ACE inhibitor or ARB + beta-blocker + diuretic and/or MRA. 1
• Add SGLT2 inhibitor for additional BP-lowering and outcome benefit. 1

Heart Failure with Preserved Ejection Fraction (HFpEF):

• SGLT2 inhibitors are recommended for modest BP-lowering and improved outcomes. 1
• ARBs and/or MRAs may be considered to reduce heart failure hospitalizations. 1

Chronic Kidney Disease (CKD):

• Use RAS blocker (ACE inhibitor or ARB) as part of the regimen, particularly with microalbuminuria or proteinuria. 1
• Target systolic BP 130–139 mmHg in diabetic or non-diabetic CKD; 120–129 mmHg if eGFR >30 mL/min/1.73 m² and tolerated. 1

Diabetes Mellitus:

• ACE inhibitor or ARB combined with CCB or thiazide-like diuretic provides renal protection and glycemic neutrality. 2, 3

Coronary Artery Disease/Post-MI:

• Beta-blocker + ACE inhibitor or ARB + CCB or thiazide diuretic. 1, 2

Stroke/TIA History:

• Target systolic BP 120–130 mmHg; use any major class combination. 1

Third-Line Agent Selection

When BP remains uncontrolled on two drugs at optimal doses, add the third agent to complete triple therapy: ACE inhibitor or ARB + CCB + thiazide-like diuretic. 1

Standard Third-Line Algorithm

1. If on ACE inhibitor/ARB + CCB: Add thiazide-like diuretic (chlorthalidone 12.5–25 mg or hydrochlorothiazide 25 mg). 1, 2

2. If on ACE inhibitor/ARB + thiazide: Add CCB (amlodipine 5–10 mg). 1, 2

3. If on CCB + thiazide: Add ACE inhibitor or ARB (ARB preferred in Black patients). 1

Special Circumstances for Third Agent

If CCB not suitable (edema, intolerance):

• Use thiazide-like diuretic as second agent, then add ACE inhibitor/ARB as third. 1

If heart failure or high heart failure risk:

• Prioritize thiazide-like diuretic over CCB. 1

If beta-blocker already prescribed (for compelling indication):

• Add CCB rather than thiazide to reduce diabetes risk. 1

Women of childbearing potential:

• Avoid ACE inhibitors and ARBs; use CCB + thiazide diuretic + beta-blocker if needed. 1

Diuretic Selection Specifics

• Preferred thiazide-like diuretics: Chlorthalidone 12.5–25 mg once daily or indapamide 1.5 mg modified-release once daily. 1, 3
• If already on bendroflumethiazide or hydrochlorothiazide with stable control: Continue current therapy. 1
• If initiating or changing: Use thiazide-like diuretic (chlorthalidone or indapamide) over conventional thiazide (bendroflumethiazide or hydrochlorothiazide). 1

Blood Pressure Targets

• General target: <130/80 mmHg for most adults; minimum acceptable <140/90 mmHg. 1, 3
• High-risk patients (diabetes, CKD, CVD): <130/80 mmHg. 1
• Elderly ≥65 years: Systolic <130 mmHg if tolerated. 1
• CKD with eGFR >30: Systolic 120–129 mmHg if tolerated. 1

Monitoring After Adding Third Agent

• Recheck BP in 2–4 weeks after any medication change. 2, 3
• Check serum potassium and creatinine 2–4 weeks after adding thiazide diuretic or RAS blocker. 1, 2
• Achieve target BP within 3 months of therapy modification. 2

Critical Pitfalls to Avoid

• Never combine ACE inhibitor with ARB: Increases hyperkalemia and acute kidney injury risk without cardiovascular benefit. 1, 2
• Do not use beta-blocker as initial or second-line therapy unless compelling indication (post-MI, HFrEF, angina, AF). 1
• Do not delay intensification: Stage 2 hypertension (≥160/100 mmHg) requires action within 2–4 weeks. 2
• Verify adherence first: Non-adherence is the most common cause of apparent treatment resistance. 2, 3
• Confirm true hypertension: Use home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) before escalating. 2

Fourth-Line Agent (Resistant Hypertension)

If BP remains ≥140/90 mmHg on optimal triple therapy, add spironolactone 25–50 mg daily as the preferred fourth agent. 1

• Alternative fourth-line options if spironolactone contraindicated: Eplerenone, amiloride, higher-dose thiazide, loop diuretic, bisoprolol, or doxazosin. 1
• Monitor potassium closely when adding spironolactone to RAS blocker. 1
• Reinforce sodium restriction <2 g/day in resistant hypertension. 1